Minimal Residual Disease as a Surrogate Endpoint for Product Development for Multiple Myeloma: Comparing FDA and EMA Guidances
Feature ArticlesTelly Chi, PharmD, MS, RAC • Aditi Sinha, PhD
Feature ArticlesTelly Chi, PharmD, MS, RAC • Aditi Sinha, PhD